These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
374 related items for PubMed ID: 20234780
1. Review of antihemophilic factor injection for the routine prophylaxis of bleeding episodes and risk of joint damage in severe hemophilia A. Rossbach HC. Vasc Health Risk Manag; 2010 Mar 03; 6():59-68. PubMed ID: 20234780 [Abstract] [Full Text] [Related]
7. Phase 4 Safety and Efficacy Study of Antihemophilic Factor (Recombinant) in Previously Treated Chinese Patients With Severe/Moderately Severe Hemophilia A. Zhao Y, Hu Y, Jin J, Zhao X, Wang X, Wu R, Wu D, Yang R, Yang F, Hu Q, Wang J, Fang H, Engl W. Clin Appl Thromb Hemost; 2021 Sep 03; 27():1076029621989811. PubMed ID: 33587652 [Abstract] [Full Text] [Related]
8. Decreased Bleeding Rates in Patients with Hemophilia A Switching from Standard-Half-Life FVIII to BAY 94-9027 Prophylaxis. Mancuso ME, Reding MT, Negrier C, Kerlin BA, Rangarajan S, Simpson ML. Thromb Haemost; 2021 Aug 03; 121(8):1079-1086. PubMed ID: 33296943 [Abstract] [Full Text] [Related]
9. [Prevention of joint damage in hemophilic children with early prophylaxis]. Kreuz W, Escuriola Ettingshausen C, Funk M, Pons S, Schmidt H, Kornhuber B. Orthopade; 1999 Apr 03; 28(4):341-6. PubMed ID: 10335528 [Abstract] [Full Text] [Related]
10. A history of prophylaxis in haemophilia. Moreno MM, Cuesta-Barriuso R. Blood Coagul Fibrinolysis; 2019 Sep 03; 30(1S Suppl 1):S1-S3. PubMed ID: 31517707 [Abstract] [Full Text] [Related]
11. Evidence for the benefits of prophylaxis in the management of hemophilia A. Hoots WK, Nugent DJ. Thromb Haemost; 2006 Oct 03; 96(4):433-40. PubMed ID: 17003919 [Abstract] [Full Text] [Related]
14. Cost-utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on-demand therapy in young children with severe haemophilia A. Risebrough N, Oh P, Blanchette V, Curtin J, Hitzler J, Feldman BM. Haemophilia; 2008 Jul 03; 14(4):743-52. PubMed ID: 18422610 [Abstract] [Full Text] [Related]
15. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. Collins PW, Björkman S, Fischer K, Blanchette V, Oh M, Schroth P, Fritsch S, Casey K, Spotts G, Ewenstein BM. J Thromb Haemost; 2010 Feb 03; 8(2):269-75. PubMed ID: 19943875 [Abstract] [Full Text] [Related]
17. How I use bypassing therapy for prophylaxis in patients with hemophilia A and inhibitors. Leissinger CA, Singleton T, Kruse-Jarres R. Blood; 2015 Jul 09; 126(2):153-9. PubMed ID: 25827834 [Abstract] [Full Text] [Related]
20. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Iorio A, Marchesini E, Marcucci M, Stobart K, Chan AK. Cochrane Database Syst Rev; 2011 Sep 07; (9):CD003429. PubMed ID: 21901684 [Abstract] [Full Text] [Related] Page: [Next] [New Search]